A Phase 3b, open-label, continuation study of prophylactic and on-demand treatment of cTTP with TAK-

• Research type

  Research Study

• Full title

  A Phase 3b, prospective, open-label, multicenter, single treatment arm, continuation study of the safety and efficacy of TAK-755 (rADAMTS-13, also known as BAX 930/SHP655) in the prophylactic and on-demand treatment of subjects with severe congenital thrombotic thrombocytopenic purpura (cTTP; Upshaw Schulman Syndrome, or hereditary thrombotic thrombocytopenic purpura)

• IRAS ID

  1003405

• Contact name

  Marie Scully

• Contact email

  m.scully@ucl.ac.uk

• Eudract number

  2020-003348-10

• Clinicaltrials.gov Identifier

  NCT04683003

• REC name

  West of Scotland REC 1

• REC reference

  20/WS/0129

• Date of REC Opinion

  17 Nov 2020

• REC opinion

  Further Information Favourable Opinion